Ischemic Heart Disease Drugs Market Report and Forecast 2024-2032

Ischemic Heart Disease Drugs Market Size

The ischemic heart disease drugs market was valued at USD 4.94 billion in 2023, driven by the rising incidence of heart diseases across the globe. The market is expected to grow at a CAGR of 4.35% during the forecast period of 2024-2032, with the values likely to attain USD 6.87 billion by 2032.

Ischemic Heart Disease Drugs Market Outlook

• In March 2024, the U.S. FDA approved Wegovy (semaglutide) injection, expanding its use to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease.

• In December 2023, the FDA approved colchicine for the prevention of heart disease. Colchicine, previously Lodoco, is now prescribed to supplement cholesterol and blood pressure medications in reducing the risk of heart disease and stroke. Such decisions by regulatory authorities is expected to impact the market positively.

• Causing 108.8 deaths per 100,000 people ischemic heart disease is a major cause of CVD deaths worldwide. Increasing incidence of the condition is propelling the market demand for ischemic heart disease drugs.

Ischemic Heart Disease Drugs Market Overview

Ischemic heart diseases are medical conditions under which the patient’s heart arteries that supply blood to the heart muscle get narrowed, lowering the blood flow. In severe cases, the patient suffers from artery blockage which is then treated surgically (if feasible). To improve the blood flow in such medical conditions, ischemic heart disease drugs are prescribed to patients. The market is expected to witness substantial growth due to the increasing prevalence of heart diseases worldwide. With the increasing prevalence, the increasing demand for ischemic heart disease drugs is corresponding.

Ischemic Heart Disease Drugs Market Growth Factors

Prevalence of Heart Diseases Boosting the Market Demand

The increasing prevalence of cardiovascular diseases is contributing to the increased demand for ischemic heart disease drugs. According to the new Global Burden of Disease (GBD) special report published in 2023, ischemic heart disease is the leading cause of death for cardiovascular disease worldwide. It causes 108.8 deaths per 100,000 people. Estimated by the Centers for Disease Control and Prevention nearly 805,000 people suffer from a heart attack every year in the United States. As a result, the demand for effective therapeutics is on the rise.

Rising Approvals by the Regulatory Authorities to Meet the Ischemic Heart Disease Drugs Market Demand

In March 2024, the U.S. Food and Drug Administration gave clearance to Wegovy (semaglutide) injection, expanding its use to reduce the risk of cardiovascular death, heart attack, and stroke in overweight or obese adults. This approval marks a significant advancement in the management of ischemic heart disease, particularly for patients at higher risk due to their weight. Wegovy is an established medication for weight management that is now additionally useful in the treatment of obesity with direct cardiovascular benefits, potentially transforming the therapeutic landscape for ischemic heart disease. The approval was based on a robust, multi-national, placebo-controlled double-blind trial involving over 17,600 participants, reinforcing the drug's efficacy and safety. This development is expected to drive increased adoption of Wegovy in cardiovascular risk management, leading to increased market penetration and potentially stimulating further research and development in cardio-metabolic drugs. Consequently, the ischemic heart disease drugs market is likely to witness significant growth, with enhanced treatment options that address both the symptoms of heart disease and risk factors such as obesity.

In December 2023, the FDA approved colchicine drug (traditionally used for gout and other inflammatory conditions) for the prevention of heart disease as well. Previously Lodoco, colchicine was approved recently to manage cholesterol levels, and blood pressure and reduce the risk of heart disease and stroke. This approval marked a significant expansion in the use of colchicine, positioning it as a potential drug in ischemic heart disease management. This approval could potentially trigger increased clinical research and investment for the repurposing of other existing drugs for cardiovascular indications, boosting the market growth.

Regulatory Authorities Expanding the Application of Drug

In March 2024, Regeneron Pharmaceuticals, Inc. announced that the U.S. Food & Drug Administration (FDA) has approved the expansion of Praluent® (alirocumab) usage to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). This approval marks a significant expansion in the treatment landscape for ischemic heart disease, as Praluent, targeting the PCSK9 enzyme, becomes one of the few therapies available to younger patients at high genetic risk of heart disease. With the expanded usage of Praluent, it will now be helpful in treating heart disease in early diagnosis and effectively managing the condition in the long term. Consequently, the market is poised for substantial growth.

Ischemic Heart Disease Drugs Market Trends

Ischemic Heart Disease Drugs Market Segmentation

Market Breakup by Disease Type

• Angina Pectoris

• Myocardial Infarction

Market Breakup by Drug Class
 

• Anti-Dyslipidemic Drugs

• Calcium Channel Blockers

• Beta-Blockers

• ACE Inhibitors

• ARBs

• Vasodilators

• Antithrombotic Agents

Market Breakup by Distribution Channel

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Ischemic Heart Disease Drugs Market Share

Angina Pectoris Leads the Market Segmentation Based on Disease Type

The market share based on disease type includes angina pectoris and myocardial infarction. The angina pectoris segment is expected to lead the market due to its high prevalence. Angina is a symptom of coronary artery disease in which chest pain is experienced by the patient due to reduced blood flow to the heart muscles. Frequent encounters drive demand for drugs to provide relief and improve patient’s quality of life.

Market Segmentation Based on Drug Class to Witness Substantial Growth

The drug class segmentation includes anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents. The drug class segmentation is dominated by anti-dyslipidemic drugs as management of blood lipid levels is necessary to avoid and treat ischemic heart diseases (IHD). These drugs include statins, fibrates, and cholesterol absorption inhibitors that are considered effective in reducing cholesterol levels. It is particularly effective in managing bad cholesterol LDL, a major risk factor for the formation of plaques in the arteries.

Ischemic Heart Disease Drugs Market Analysis by Region

Based on the regions, the market report covers the United States, EU-4 (Germany, France, Italy, Spain) and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. United States is leading the market share with the presence of a robust healthcare infrastructure to provide high-end treatments to patients. The increasing prevalence of people suffering from heart diseases such as coronary artery disease (CAD), arrhythmias, cardiomyopathy, and valvular heart diseases, among others is collectively driving the demand for ischemic heart disease drugs in the region. Data from the Centers for Disease Control and Prevention states that in the United States, every 33 seconds cardiovascular disease claims a human life. The annual expenditure on heart disease amounted to USD 239.9 billion from 2018 to 2019.

Leading Players in the Ischemic Heart Disease Drugs Market

The key features of the market report include patent analysis, clinical trials analysis, grants, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Eli Lilly and Company

Eli Lilly and Company was established in 1876 and is currently headquartered in Indianapolis, Indiana, USA. The company is focused on developing and distributing effective medications for various including endocrinology, oncology, immunology, neuroscience, and cardiovascular diseases.

Bayer AG

Founded in 1863, Bayer AG is a prominent pharmaceutical company focused on cardiology, hematology and oncology related prescription drugs. Some notable products in the cardiovascular domain include aspirin, Xarelto (rivaroxaban), and Eylea (aflibercept) among others.

Pfizer Inc.

Headquartered in New York, USA, this company was established in 1849. The company has a strong product portfolio of cardiovascular diseases as well as continuously takes part in research initiatives for providing a diverse range of medications to consumers.

Other players in the market include Sanofi, Novartis AG, Baxter International, Inc., Merck & Co., Inc., Johnson & JohnsonServices, Inc., Amgen Inc., Boehringer Ingelheim International GmbH

F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Bristol-Myers Squibb Company, and Eisai Co., Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report. 

Key Highlights of the Report

Key Queries Solved in the Ischemic Heart Disease Drugs Market Report

• What was the ischemic heart disease drugs market value in 2023?  
• What is the ischemic heart disease drugs market forecast outlook for 2024-2032?  
• What are the major factors aiding the global market demand?  
• What are the major market trends? 
• What is the market segmentation based on the disease type?
• What is the market segmentation based on the distribution channel?
• What is the market breakup by drug class?
• What are the major markets according to the EMR report? 
• Who are the key players involved in the ischemic heart disease drugs market?
• How will the market landscape evolve in the upcoming years? 
• What are the major drivers, opportunities, and restraints in the market? 
• What will be the effect of each driver, challenge, and opportunity on the market? 
• Which country is poised to lead the market share in the forecast period? 
• Which segment has the highest impact on the market size? 
• How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?